Cargando…
P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
Autores principales: | Sridharan, Meera, Padrnos, Leslie, Wysokinska, Ewa, Pruthi, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430327/ http://dx.doi.org/10.1097/01.HS9.0000973340.23733.b0 |
Ejemplares similares
-
Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19–Positive Compared With COVID-19–Negative Patients
por: Chaudhary, Rahul, et al.
Publicado: (2021) -
No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
por: Houghton, Damon E., et al.
Publicado: (2022) -
Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019) -
Deep Vein Thrombosis after COVID-19 Vaccinations
por: Houghton, Damon E., et al.
Publicado: (2021) -
Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)